While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...

Laura Gibson is an associate professor of medicine and of pediatrics at UMass Chan Medical School. CMV belongs to the same virus family as cold sores and chickenpox and, like those viruses, lives in ...

The U.S. Centers for Disease Control and Prevention (CDC) has advised people to be wary of cytomegalovirus (CMV) during the holiday season. CMV is a common virus for people of all ages that is usually ...

March 19, 2009 — Cytomegalovirus (CMV) glycoprotein B vaccine may help prevent maternal and congenital CMV infection, according to the results of a phase 2, randomized, double-blind, controlled trial ...

Moderna (NASDAQ:MRNA) announced that its late-stage trial for the mRNA-1647 vaccine, aimed at preventing cytomegalovirus infection, did not achieve its primary objective. The stock is down 3.9% after ...